Clinical Trial Update: Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating non-psychoactive cannabidiol as an adjunct to botulinum toxin for blepharospasm has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharospasm

Drugs mentioned

• Botulinum toxin (botulinum toxin)
• Cannabidiol (non-psychoactive CBD) (cannabidiol)

Snippet

Sponsor: Silkiss Eye Surgery | Conditions: Blepharospasm, Blepharospasm, Benign Essential | Phase 2, Phase 3 | Status: COMPLETED